- Home
- RBOT vs AVTX Comparison
RBOT vs AVTX Comparison
Compare RBOT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | AVTX |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 339.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RBOT | AVTX |
|---|---|---|
| Price | $1.98 | $16.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $7.00 | ★ $32.57 |
| AVG Volume (30 Days) | 62.5K | ★ 547.6K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $1.71 | $3.39 |
| 52 Week High | $13.75 | $20.72 |
Technical Indicators
Market Signals| Indicator | RBOT | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 51.66 |
| Support Level | $1.76 | $15.36 |
| Resistance Level | $2.41 | $19.26 |
| Average True Range (ATR) | 0.20 | 1.29 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 38.63 | 58.62 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).